Get the Stockscreener App
264.88
2.37%
-6.426
After Hours:
264.91
0.026
+0.01%
Insulet Corporation stock is traded at $264.88, with a volume of 1.48M.
It is down -2.37% in the last 24 hours and down -8.23% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$271.31
Open:
$268.18
24h Volume:
1.48M
Relative Volume:
2.06
Market Cap:
$18.63B
Revenue:
$2.36B
Net Income/Loss:
$236.10M
P/E Ratio:
80.61
EPS:
3.286
Net Cash Flow:
$382.50M
1W Performance:
-6.81%
1M Performance:
-8.23%
6M Performance:
-8.73%
1Y Performance:
-3.99%
1-Day Range:
$261.95
$270.61
1-Week Range:
$261.95
$288.98
52-Week Range:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
264.88 | 19.09B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-16-25 | Initiated | Evercore ISI | Outperform |
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Ownership Capital B.V. Sells 103,193 Shares of Insulet Corporation $PODD - MarketBeat
Pier 88 Investment Partners LLC Raises Stock Position in Insulet Corporation $PODD - MarketBeat
Cowen assumes coverage on Insulet stock with Hold rating - Investing.com
Strs Ohio Has $5.15 Million Position in Insulet Corporation $PODD - MarketBeat
Published on: 2026-01-27 12:20:42 - baoquankhu1.vn
Here's Why Insulet (PODD) is a Strong Growth Stock - Nasdaq
Y Intercept Hong Kong Ltd Sells 9,830 Shares of Insulet Corporation $PODD - MarketBeat
How (PODD) Movements Inform Risk Allocation Models - Stock Traders Daily
Insulet Corporation $PODD Shares Sold by Teacher Retirement System of Texas - MarketBeat
Insulet Corporation $PODD Shares Sold by Baillie Gifford & Co. - MarketBeat
Insulet Stock Is Going Off: Game-Changer Buy Or Overhyped Trap? - AD HOC NEWS
Insulet Corporation (NASDAQ:PODD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insulet Completes Key Omnipod 5 SmartAdjust 2.0 Study, Setting Up Next Growth Phase - TipRanks
What You Need To Know Ahead of Insulet’s Earnings Release - Barchart.com
Universal Beteiligungs und Servicegesellschaft mbH Sells 4,979,945 Shares of Insulet Corporation $PODD - MarketBeat
BVI appoints Jim Hollingshead as CEO - MedTech Dive
SG Americas Securities LLC Has $831,000 Stock Holdings in Insulet Corporation $PODD - MarketBeat
Is Insulet (PODD) the Future of Diabetes Management? - Nasdaq
VIX Spike: Is Insulet Corporation a play on infrastructure spendingRecession Risk & Fast Gain Stock Tips - baoquankhu1.vn
BVI Appoints Jim Hollingshead as President & Chief Executive Officer - GlobeNewswire Inc.
PODD stock benefits from FDA approval of Omnipod 5's enhancements - MSN
Chart Watch: What drives SWAGWs stock priceWeekly Stock Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
Insulet Corporation $PODD Shares Purchased by Stephens Investment Management Group LLC - MarketBeat
Goldman Sachs Adjusts Price Target on Insulet to $363 From $365, Maintains Buy Rating - marketscreener.com
Nisa Investment Advisors LLC Sells 4,201 Shares of Insulet Corporation $PODD - MarketBeat
Wells Fargo Sticks to Their Buy Rating for Insulet (PODD) - The Globe and Mail
Bernstein Reduces Firm's PT on Insulet (PODD) Stock - Finviz
Bernstein Reduces Firm’s PT on Insulet (PODD) Stock - Insider Monkey
Bernstein reduces firm’s PT on Insulet (PODD) stock - MSN
Nordea Investment Management AB Has $125.13 Million Position in Insulet Corporation $PODD - MarketBeat
Insulet Corp (NASDAQ:PODD) Passes Key Growth Screen with Strong Momentum - Chartmill
Insulet Stock Is Going Off: Game-Changer For Diabetes Tech Or Just Hype? - AD HOC NEWS
Investment Recap: Will Insulet Corporation stock benefit from AI adoptionPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Trading Systems Reacting to (PODD) Volatility - Stock Traders Daily
Insulet Corporation (PODD) Stock Analysis: A 29.95% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Insulet Shares Fall After Barclays Downgrade - marketscreener.com
Barclays downgrades Insulet stock rating to Underweight on competition concerns - Investing.com
Insulet (PODD) Downgraded by Barclays with Lowered Price Target - GuruFocus
Barclays Downgrades Insulet to Underweight From Equal Weight, Adjusts Price Target to $274 From $316 - marketscreener.com
Barclays downgrades DexCom, Insulet as diabetes competition seen intensifying in 2 - Investing.com
Insulet (PODD) Downgraded by Barclays Amid Growing Competition - GuruFocus
Barclays Downgrades Insulet Corporation (PODD) to Underweight - StreetInsider
Insulet (NASDAQ:PODD) Downgraded to Equal Weight Rating by Barclays - MarketBeat
Aug Movers: Can Insulet Corporation ride the EV waveJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
Insulin Patch Pump Market Is Going to Boom | Medtronic • Insulet Corporation • Tandem Diabetes Care - openPR.com
Why Analysts See The Insulet (PODD) Story Shifting As Omnipod Growth Meets Valuation Questions - Yahoo Finance
150,699 Shares in Insulet Corporation $PODD Bought by Parnassus Investments LLC - MarketBeat
Bernstein Lowers Price Target for Insulet (PODD) to $380, Mainta - GuruFocus
Assessing Insulet (PODD) Valuation After CES 2026 Spotlight On Omnipod 5 And Growth Prospects - Sahm
Precision Medicine and the Tubeless Revolution: An In-Depth Look at Insulet Corporation (PODD) - FinancialContent
Bernstein Adjusts Price Target on Insulet to $380 From $410, Maintains Outperform Rating - marketscreener.com
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):